Stock comparison
Haemonetics
Incyte
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
INCY
Incyte
Market cap
$19.41B
Sector
Healthcare
Overall winner
Incyte INCY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | INCY | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 63C | HAE |
| Benjamin Graham | 85A | 73B | HAE |
| Philip Fisher | 60C | 61C | INCY |
| Peter Lynch | 54C | 50C | HAE |
| Joel Greenblatt | 31F | 45D | INCY |
| Charlie Munger | 54D | 60C | INCY |
| Terry Smith | 55D | 66B | INCY |
Side-by-side metrics
| Metric | HAE | INCY |
|---|---|---|
| Market cap | $2.98B | $19.41B |
| P/E (TTM) | 24.8x | 14.0x |
| EV/EBIT | 14.1x | 12.4x |
| ROIC (TTM) | 8.37% | 19.98% |
| Gross margin | 55.74% | 91.86% |
| Net margin | 7.29% | 26.71% |
| Revenue CAGR 5y | 7.65% | 14.55% |
| EPS CAGR 5y | 24.62% | 11.26% |
| Debt / Equity | 1.5x | 0.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- EPS CAGR 5y24.62%vs 11.26%+54%
INCY leads on
- Debt / Equity0.0xvs 1.5x+100%
- Market cap$19.41Bvs $2.98B+85%
- Net margin26.71%vs 7.29%+73%
- ROIC (TTM)19.98%vs 8.37%+58%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.